NDC product
RETEVMO
NDC 0002-6120 · Eli Lilly and Company
Key facts
| Product NDC | 0002-6120 |
|---|---|
| Proprietary name | RETEVMO |
| Nonproprietary name | selpercatinib |
| Substances | SELPERCATINIB |
| Dosage form | TABLET, COATED |
| Route | ORAL |
| Labeler | Eli Lilly and Company |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA218160 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] and 1 more |
| Marketing start | Apr 10, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: